Upgrade to SI Premium - Free Trial

Alkermes (ALKS)

52.58 -0.27 (0.51%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/28/26)

Latest Headlines

Alkermes (ALKS) PT Raised to $63 at Stifel July 20, 2026 5:14 AM - StreetInsider Alkermes to Report Second Quarter Financial Results on July 28, 2026 July 14, 2026 4:00 PM - BizWire Alkermes (ALKS) PT Raised to $57 at TD Cowen July 13, 2026 9:20 AM - StreetInsider Alkermes drug shows sustained narcolepsy benefits at nine months July 13, 2026 7:01 AM - StreetInsider Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis July 13, 2026 7:00 AM - BizWire JPMorgan Resumes Alkermes (ALKS) at Neutral July 13, 2026 3:13 AM - StreetInsider Alkermes terminates authorized generic supply deal with Amneal July 8, 2026 8:10 AM - StreetInsider Form 8-K Alkermes plc. For: Jul 06 July 8, 2026 8:00 AM - SEC Filing Form 4 Alkermes plc. For: Jul 06 Filed by: Gaffin David Joseph July 6, 2026 4:48 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph July 6, 2026 4:18 PM - SEC Filing Alkermes (ALKS) PT Raised to $65 at Mizuho July 2, 2026 5:04 AM - StreetInsider Form 4 Alkermes plc. For: Jul 01 Filed by: Hopkinson Craig C. July 1, 2026 6:29 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. July 1, 2026 4:13 PM - SEC Filing BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns June 29, 2026 11:51 AM - StreetInsider Alkermes (ALKS) PT Raised to $65 at Wells Fargo June 29, 2026 6:33 AM - StreetInsider BofA Securities Downgrades Alkermes (ALKS) to Underperform June 29, 2026 6:05 AM - StreetInsider Alkermes (ALKS) PT Raised to $61 at Needham June 24, 2026 7:11 AM - StreetInsider Alkermes (ALKS) PT Raised to $50 at TD Cowen June 22, 2026 8:26 AM - StreetInsider Alkermes (ALKS) PT Raised to $54 at Needham June 18, 2026 7:05 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS) June 18, 2026 6:43 AM - StreetInsider Alkermes narcolepsy drug meets phase 2 trial endpoints June 17, 2026 4:15 PM - StreetInsider Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 June 17, 2026 4:15 PM - BizWire Form 8-K Alkermes plc. For: Jun 15 June 15, 2026 7:10 AM - SEC Filing Alkermes receives orphan drug status for alixorexton in U.S. and Europe June 15, 2026 7:02 AM - StreetInsider Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe June 15, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: Jun 12 Filed by: Wright Christopher I June 12, 2026 8:04 PM - SEC Filing Form 144 Alkermes plc. Filed by: Wright Christopher I June 12, 2026 4:19 PM - SEC Filing Alkermes (ALKS) PT Raised to $56 at RBC Capital; 'Don't Sleep On The Pipeline' June 9, 2026 7:33 AM - StreetInsider Form 4 Alkermes plc. For: Jun 04 Filed by: Gaffin David Joseph June 4, 2026 5:00 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph June 4, 2026 4:17 PM - SEC Filing Alkermes to present sleep medicine research at SLEEP 2026 conference June 4, 2026 7:00 AM - StreetInsider Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research June 4, 2026 7:00 AM - BizWire Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference June 3, 2026 4:05 PM - BizWire Form 4 Alkermes plc. For: Jun 01 Filed by: Hopkinson Craig C. June 1, 2026 7:27 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. June 1, 2026 4:30 PM - SEC Filing Form 4 Alkermes plc. For: May 29 Filed by: Parisi Samuel Joseph May 29, 2026 6:03 PM - SEC Filing Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting May 26, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: May 20 Filed by: Wright Christopher I May 22, 2026 8:08 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Wilson Frank Anders May 22, 2026 8:07 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: snyderman nancy lynn MD May 22, 2026 8:05 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: MCKEON BRIAN P May 22, 2026 8:04 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Lurker Nancy May 22, 2026 8:02 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: LAURENCIN CATO T May 22, 2026 8:01 PM - SEC Filing Form 4/A Alkermes plc. For: May 20 Filed by: GAYNOR RICHARD May 22, 2026 8:00 PM - SEC Filing Form 4/A Alkermes plc. For: May 20 Filed by: Cooke Shane May 22, 2026 7:58 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: GAYNOR RICHARD May 22, 2026 4:59 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Cooke Shane May 22, 2026 4:58 PM - SEC Filing Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences May 21, 2026 7:00 AM - BizWire Form 8-K Alkermes plc. For: May 20 May 20, 2026 4:11 PM - SEC Filing Form SCHEDULE 13G/A Alkermes plc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/ May 15, 2026 10:09 AM - SEC Filing Form DEFA14A Alkermes plc. May 13, 2026 5:03 PM - SEC Filing Alkermes (ALKS) PT Raised to $48 at Baird May 13, 2026 6:23 AM - StreetInsider TD Cowen on Alkermes (ALKS): 'Lumryz's true once nightly profile should support uptake in a large market' May 12, 2026 9:30 AM - StreetInsider Form 8-K Alkermes plc. For: May 12 May 12, 2026 7:08 AM - SEC Filing Alkermes reports positive phase 3 trial results for LUMRYZ in sleep disorder May 12, 2026 7:00 AM - StreetInsider Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia May 12, 2026 7:00 AM - BizWire Alkermes (ALKS) PT Raised to $48 at UBS May 6, 2026 9:22 AM - StreetInsider Alkermes (ALKS) PT Raised to $44 at Wells Fargo May 6, 2026 8:46 AM - StreetInsider Alkermes (ALKS) PT Raised to $50 at Needham May 6, 2026 7:22 AM - StreetInsider Form 10-Q Alkermes plc. For: Mar 31 May 5, 2026 4:31 PM - SEC Filing Alkermes (ALKS) PT Raised to $45 at Stifel May 5, 2026 12:28 PM - StreetInsider Alkermes (ALKS) Tops Q1 EPS by 14c; offers guidance May 5, 2026 7:13 AM - StreetInsider Form 8-K Alkermes plc. For: May 05 May 5, 2026 7:05 AM - SEC Filing Alkermes plc Reports First Quarter 2026 Financial Results May 5, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: May 04 Filed by: Gaffin David Joseph May 4, 2026 8:43 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph May 4, 2026 4:31 PM - SEC Filing Form 4 Alkermes plc. For: May 01 Filed by: Hopkinson Craig C. May 1, 2026 9:05 PM - SEC Filing Form 8-K/A Alkermes plc. For: Feb 12 May 1, 2026 4:52 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. May 1, 2026 4:22 PM - SEC Filing Form SCHEDULE 13G Alkermes plc. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 28, 2026 2:46 PM - SEC Filing Form SCHEDULE 13G Alkermes plc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 28, 2026 11:18 AM - SEC Filing Full Article List